Vanguard Portfolio Management’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
Other funds holding PLX
Vanguard Portfolio Management's PLX Position: Q3 2026 in Review
Vanguard Portfolio Management increased its Protalix BioTherapeutics (PLX) stake by 9.1% in Q3 2026, buying an estimated $116K and bringing the position to 557,199 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2798.
Vanguard Portfolio Management first reported a position in PLX in Q1 2026 and has held it in 3 quarters since. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.
- Vanguard Portfolio Management held 557,199 shares of Protalix BioTherapeutics worth $1.54M as of Q3 2026.
- Vanguard Portfolio Management bought 46,560 Protalix BioTherapeutics shares in Q3 2026, an estimated $116K.
- Protalix BioTherapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #2798 holding.
- Vanguard Portfolio Management first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 3 quarters since.
- 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.